Signals flagged in the original
Provisional estimate — refines shortly Full breakdown ↓
A study has revealed that type 2 diabetes patients using dihydropyridine calcium-channel blockers (DCCBs) are at a 33% increased risk of complications such as kidney disease. This highlights the importance of monitoring the effects of these medications in diabetic patients.
Our neutral summary
A study has revealed that type 2 diabetes patients using dihydropyridine calcium-channel blockers (DCCBs) are at a 33% increased risk of complications such as kidney disease. This highlights the importance of monitoring the effects of these medications in diabetic patients.
The reporting belongs to Daily Mail; we don't reproduce it.
No note attached
on this article.
Millions taking common blood pressure medication at risk of deadly kidney disease, top experts warn
Study finds increased risk of kidney disease in diabetes patients using certain blood pressure medications